TWiV 1106: Clinical update with Dr. Daniel Griffin

April 20, 2024

In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of measles before addressing results of Pfizer’s phase 3 RSV vaccine clinical trial for adults under 60, RSV, influenza and SARS-CoV-2 circulation, differences between rural and urban communities dealing with SARS-CoV-2 infections, the latest statistics on influenza and COVID-19 circulation, restates the guidelines for spring administration of COVID vaccines boosters, discusses the emergency use application of a pre-exposure prophylactic. revised guidelines for how to treat respiratory viral infection guidelines by the CDC, continues to dispel the myth of viral rebound, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, how long COVID affects the brain and associates with an increase in allergic incidents as well as if post SARS-CoV-2 infected patients are unable to exercise or have functional limitations. For more information about this body of work, listen to TWiV 1088.

Click arrow to play
Download TWiV 1106 (32 MB .mp3, 44 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Measles tracking (CDC)

Influenza risk factors for potential severe outcomes (OFID)

COVID-19 national trend (CDC)

Does SARS-CoV-2 infection influence sperm quality (Scientific Reports)

Spring COVID-19 booster recommendations (CIDRAP)

Older adult spring booster available (CDC)

Advisory committee for immunization practices slides (CDC)

Advisory committee for immunization practices spring 2024 COVID-19 boosters (CDC)

Slide 19 (CDC)

EUA for pemgarda (FDA)

CDC Quarantine guidelines (CDC)

NIH COVID-19 treatment guidelines (NIH)

Infectious Disease Society guidelines for treatment and management (IDSociety)

Nirmatrelvir for vaccinated or unvaccinated COVID-19 patients (NEJM)

Nirmatrelvir/ritonavir vs. remdesivir for treatment of high risk outpatients (Therapeutic Advances in Infectious Disease)

Molnupiravir safety and efficacy (JMV)

Convalescent plasma recommendation for immunocompromised (IDSociety)

Outpatient treatment with concomitant vaccine-boosted convalescent plasma (mBio)

Updated respiratory virus guidances (CDC)

What do when your heathcare provider is infected with SARS-CoV-2 (CDC)

Managing healthcare staffing shortages (CDC)

Steroids,dexamethasone at the right time (OFID)

Anticoagulation guidelines ( Long COVID evidence based review TWiV shout out (TWiV 1088)

Contribute to our ASTMH fundraiser at PWB

Letters read on TWiV 1106

Dr. Griffin’s COVID treatment summary (pdf)

Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

The post TWiV 1106: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.

Leave a Reply

Your email address will not be published. Required fields are marked *